Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.ACET · Entity 6860 | Director · President & CEO | June 19, 2026 | June 23, 2026 |
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | Director | October 24, 2018 | December 21, 2018 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date June 19, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2036-06-18 | Direct | 55,000 |
Reported balance
After 2026-06-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-19 · Grant · Acquired 55,000 · Balance 55,000 F1: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date with partial acceleration tied to certain performance milestones, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date with partial acceleration tied to certain performance milestones, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.
BRAINSTORM CELL THERAPEUTICS INC.
Report date October 24, 2018 · Filed December 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,000 |
Reported balance
After 2018-10-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-10-24 · Gift · Disposed 121,558 · Balance 4,000 F1: These shares were previously reported as directly beneficially owned but on October 24, 2018 were gifted to an irrevocable trust for the benefit of the reporting person and other individuals. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2: Includes the November 30, 2018 acquisition of 2,000 shares by the reporting person, as reported on Form 4 filed November 30, 2018. |
| Common StockSEC Table I · non-derivative | IndirectBy The C. Schor Irrevocable Trust | 121,558 |
Reported balance
After 2018-10-24 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-10-24 · Gift · Acquired 121,558 · Balance 121,558 F1: These shares were previously reported as directly beneficially owned but on October 24, 2018 were gifted to an irrevocable trust for the benefit of the reporting person and other individuals. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were previously reported as directly beneficially owned but on October 24, 2018 were gifted to an irrevocable trust for the benefit of the reporting person and other individuals. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F2: Includes the November 30, 2018 acquisition of 2,000 shares by the reporting person, as reported on Form 4 filed November 30, 2018.
Karyopharm Therapeutics Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,508 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 15,508 · Balance 15,508 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 25, 2020 Filed Nov 30, 2020 21:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 32,800 | $0.00 Strike: $14.75 | $0.00 |
DisclosureSEC source: 0001209191-20-060730 · doc4.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,800 Underlying: Common Stock · 32,800 shares Expires 2030-11-24 F1 · derivative.exercise_date: This option was granted on November 25, 2020. The shares underlying this option vest as to one-third (1/3) of the shares on November 25, 2021 and as to the remaining two-thirds (2/3) of the shares in 24 equal monthly installments thereafter. Read SEC document |
| October 23, 2020 Filed Oct 28, 2020 01:42 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Tax withholdingCommon Stock | 8,649 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-029358 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,499 F1 · shares: The Reporting Person is disposing of 8,649 restricted stock units as a result of a revised tax rate for such restricted stock units. Read SEC document |
| October 23, 2020 Filed Apr 1, 2021 22:40 UTC Amendment | Adicet Bio, Inc. ACET · Entity 6860 | Tax withholdingCommon Stock | 8,649 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-014397 · doc4a.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,070 F1 · shares: The Reporting Person is disposing of 8,649 restricted stock units as a result of a revised tax rate for such restricted stock units. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 01:51 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 872,111 | $0.00 Strike: $16.11 | $0.00 |
DisclosureSEC source: 0000899243-20-025647 · doc4.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 872,111 Underlying: Common Stock · 872,111 shares Expires 2030-09-16 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries. Read SEC document |
| December 06, 2019 Filed Dec 6, 2019 22:22 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 258,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0000899243-19-028704 · doc4.xml · derivative · entry 3 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,000 Underlying: Common Stock · 258,000 shares Expires 2029-12-05 F3 · derivative.exercise_date: 25% of the shares shall vest on December 6, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 06, 2019 Filed Dec 6, 2019 22:22 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantCommon Stock | 344,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-028704 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 669,000 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSU"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest in four (4) annual installments, with the first tranche vesting on December 6, 2020. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 22:36 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 214,000 | $0.00 Strike: $8.53 | $0.00 |
DisclosureSEC source: 0000899243-19-005280 · doc4.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,000 Underlying: Common Stock · 214,000 shares Expires 2029-02-26 F1 · derivative.exercise_date: 25% of the shares shall vest on February 27, 2020, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| November 30, 2018 Filed Nov 30, 2018 22:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-062657 · tv507907_4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,558 F1 · shares: Shares acquired are shares of restricted stock awarded on November 30, 2018 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on December 30, 2018 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| November 05, 2018 Filed Dec 18, 2018 02:12 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-031272 · doc4.xml · nonDerivative · entry 6 Schor Chen · CIK 0001340875 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 F6 · balance_after: On November 5, 2018, the reporting person transferred 6,000 shares of common stock to the Schor Irrevocable Trust. The reporting person disclaims Section 16 beneficial ownership of these shares except to the extent, if any, of the reporting person's pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 24, 2018 Filed Dec 21, 2018 21:33 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GiftCommon Stock | 121,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-066056 · tv509467_4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The C. Schor Irrevocable Trust Disclosed balance after: 121,558 F1 · shares: These shares were previously reported as directly beneficially owned but on October 24, 2018 were gifted to an irrevocable trust for the benefit of the reporting person and other individuals. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| October 24, 2018 Filed Dec 21, 2018 21:33 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GiftCommon Stock | 121,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-066056 · tv509467_4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · shares: These shares were previously reported as directly beneficially owned but on October 24, 2018 were gifted to an irrevocable trust for the benefit of the reporting person and other individuals. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2 · balance_after: Includes the November 30, 2018 acquisition of 2,000 shares by the reporting person, as reported on Form 4 filed November 30, 2018. Read SEC document |
| October 15, 2018 Filed Dec 18, 2018 02:12 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-031272 · doc4.xml · nonDerivative · entry 5 Schor Chen · CIK 0001340875 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 943,000 F5 · ownership.nature: On October 15, 2018, the reporting person's spouse transferred 25,000 shares of common stock to a revocable trust of which the spouse is the trustee (the "Spousal Revocable Trust"). On the same date, the reporting person's spouse transferred 275,000 shares to a grantor retained annuity trust (the "Spousal GRAT"). The reporting person disclaims Section 16 beneficial ownership of all such shares except to the extent, if any, of the reporting person's pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 15, 2018 Filed Dec 18, 2018 02:12 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GiftCommon Stock | 643,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-031272 · doc4.xml · nonDerivative · entry 4 Schor Chen · CIK 0001340875 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 943,000 F4 · ownership.nature: On October 15, 2018, the reporting person's spouse transferred 643,000 shares of common stock to an irrevocable family trust having an independent trustee (the "Spousal Irrevocable Trust"). The reporting person disclaims Section 16 beneficial ownership of these shares except to the extent, if any, of the reporting person's pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 15, 2018 Filed Dec 18, 2018 02:12 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-031272 · doc4.xml · nonDerivative · entry 3 Schor Chen · CIK 0001340875 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,000 F3 · balance_after: On October 15, 2018, the reporting person transferred 25,000 shares of common stock to a revocable family trust of which the reporting person is the trustee (the "Schor Revocable Trust"). The reporting person disclaims Section 16 beneficial ownership of such shares except to the extent, if any, of the reporting person's pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. On the same date, the reporting person transferred 325,000 shares to a grantor retained annuity trust, which shares are included in the reporting person's direct ownership. Read SEC document |
| October 15, 2018 Filed Dec 18, 2018 02:12 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GiftCommon Stock | 593,363 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-031272 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,000 F2 · balance_after: On October 15, 2018, the reporting person transferred 593,363 shares of common stock to an irrevocable family trust having an independent trustee (the "Schor Irrevocable Trust"). The reporting person disclaims Section 16 beneficial ownership of these shares except to the extent, if any, of the reporting person's pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document |
| July 06, 2018 Filed Dec 18, 2018 02:12 UTC | Adicet Bio, Inc. TORC · Entity 6860 | GiftCommon Stock | 943,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-031272 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 949,363 F1 · balance_after: On July 6, 2018, the reporting person transferred 943,000 shares of common stock to his spouse. The reporting person disclaims Section 16 beneficial ownership of these shares except to the extent, if any, of the reporting person's pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Following this transfer, the reporting person directly held 949,363 shares and his spouse directly held 943,000 shares. Read SEC document |
| April 16, 2018 Filed Apr 17, 2018 12:08 UTC | Adicet Bio, Inc. TORC · Entity 6860 | PurchaseCommon Stock | 2,000 | $8.95 | $17,906.60 |
DisclosureSEC source: 0000899243-18-010241 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,892,363 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.9531 to $8.9533, inclusive. The reporting person undertakes to provide to resTORbio, Inc., any security holder of resTORbio, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| April 11, 2018 Filed Apr 12, 2018 11:32 UTC | Adicet Bio, Inc. TORC · Entity 6860 | PurchaseCommon Stock | 2,000 | $9.36 | $18,724.20 |
DisclosureSEC source: 0000899243-18-010033 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,890,363 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.2748 to $9.412, inclusive. The reporting person undertakes to provide to resTORbio, Inc., any security holder of resTORbio, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| April 10, 2018 Filed Apr 11, 2018 12:06 UTC | Adicet Bio, Inc. TORC · Entity 6860 | PurchaseCommon Stock | 2,000 | $8.46 | $16,914.80 |
DisclosureSEC source: 0000899243-18-009908 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,888,363 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.4048 to $8.4769, inclusive. The reporting person undertakes to provide to resTORbio, Inc., any security holder of resTORbio, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 21:36 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-058397 · tv479017_4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,558 F1 · shares: Shares acquired are shares of restricted stock awarded on November 10, 2017 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on December 10, 2017 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.